BRCA test (for breast and ovarian cancer risk)
BRCA1 and BRCA2 gene mutations are the major risk factors that are responsible for breast and ovarian cancer. BRCA test detects both inherited and de novo mutations, thus allowing to adapt treatment strategies to each patient and prescribe customized therapy methods.
Breast cancer screenings consist of a physical examination of the breasts (manual check), looking for changes in the breast tissue with ultrasound and mammography. These methods enable the doctor to detect only the changes which have already appeared in the breast tissue. Cancerous tissue may have already formed.
Ovarian cancer is usually diagnosed only after the symptoms occur. Among the patients with ovarian cancer, only 20% are diagnosed at an early stage. And an even lower percentage of women find out they have ovarian cancer before they display symptoms.
Without genetic testing, most women with BRCA1 and BRCA2 gene mutations will not be aware of the risk before the cancer develops, because standard diagnostic procedures only allow already existing changes in the tissues to be detected .
The test is usually prescribed by the family doctor, oncologist, mammologist or geneticist. Please register for this test in advance.
The test is done on a blood sample.
BRCA test (for breast and ovarian cancer risk)price
What factors affect the price?
The prices indicated below apply to citizens of the Republic of Lithuania and the European Union.
If you are coming from another country please check the price by telephoning or sending an email.
When are the examinations are carried out:
Why it is worth
To be examined at our Centre?
- This is a safe, quick and the most accurate test available at the moment.
- We perform high quality tests which has been confirmed by the ISO 15189 certification of our laboratory.
- The results of the tests performed in our laboratory are explained by our staff, a service that is provided by only a few laboratories in the country.
- There is no risk of damage or mix-up of test samples during transportation, which statistically is one of the leading causes for ruined blood samples in labs.
Good to know
Advantages of the test:
- comprehensive: full gene sequencing of BRCA1 and BRCA2. All pathogenic variants of these genes are detected;
- accurate: the highest sensitivity and specificity. The main test procedures are CE-IVD* and ISO 13485 certified. Swiss quality;
- timely: women of any age can be tested. Early diagnosis enables the patient to take the most effective precaution.
How will I get my test results?
- The report with the test results will be prepared in 14 business days.
It can be picked up at the reception or we can send it via email at your request.
- Unsure how to interpret the results? Call the lab, phone: (8 5) 247 64 22.
What to do if gene mutations are detected?
If a patient tests positive, i.e. BRCA1 and BRCA2 mutations are detected, she will need to consult a geneticist. The goal of the consultation is to make the further health care plan for the patient, give recommendations for other members of the family and discuss breast and ovarian cancer precaution.
If pathogenic mutations in BRCA genes are not detected, we recommend that the patient share the test results with her gynaecologist or mammologist.
FAQ (frequently asked questions)
The results of genetic testing stay the same throughout the lifetime, repeating the test is not necessary.
If a BRCA gene mutation is detected in the family, we recommend that the children undergo the tests once they are grown up, women can be tested from 20 years of age.
The significance of gene mutation detection is enormous and concerns not only the physical risk for you and your family members of getting cancer—knowing it can have a psychological and financial impact on the whole family. First-degree relatives of a BRCA gene mutation carrier have a much higher risk of developing cancer. Every child of the BRCA mutation carrier has a 50% chance of inheriting the mutation. If a family member gets cancer before 40 years old, it means that the whole family is at an increased risk. About 50% of women who happen to have mutations in their BRCA1 and BRCA2 genes do not have cases of breast or ovarian cancer in their family history. So, they are not aware that they could be carriers of cancer-causing mutations.